SLU-PP-332

SLU-PP-332 turns on the same cell switches that endurance exercise turns on, prompting cells to build more mitochondria, the parts that make energy, and to burn more fat. It does this through chemistry rather than training, which is why it is called an exercise mimetic. Researchers describe it as a pan-agonist of the estrogen-related receptors, mainly ERR-alpha, which are gene-controlling proteins in the cell nucleus that run the aerobic gene program. These receptors are present in heart, brain, kidney, liver, fat and gut, so the effect is not limited to one tissue, and as of June 2026 there is no registered or completed human trial and no published human pharmacokinetic study.

Seen in studies: in mouse studies at 25 to 50 mg/kg for up to 28 days there was no obvious toxicity, no sickness-related weight loss, no liver-enzyme signal at the doses tested and no heart dysfunction. In a mouse heart-failure model it improved heart function, and in an aged-kidney model it protected the kidney. No serious adverse events have been reported in any published rodent study at the doses and durations tested.

Reported by users: informal community reports mention appetite changes, although food intake was not significantly altered in the obese-mouse studies, along with a more stimulated feeling, disrupted sleep and a higher resting heart rate. None of this has controlled human data behind it.

Not ruled out: there is no human safety data at all, no Phase 1 trial and no long-term animal toxicology study beyond 12 weeks in any species. ERR receptors sit in many tissues at once, ERR-alpha takes part in some cancer-metabolism pathways, chronic high-dose human heart data do not exist, and how the human liver processes the compound, including CYP pathway interactions, is uncharacterized.

People who are pregnant or breastfeeding: no safety data exist for this group.

People under 18: no safety data exist for this group.

People with active or recent cancer: ERR-alpha takes part in some cancer-metabolism pathways, so cancer risk questions remain open.

People with known heart disease, irregular heart rhythm or uncontrolled high blood pressure: there is no chronic high-dose human data.

People with significant liver or kidney impairment: how the human liver handles the compound and its drug interactions are uncharacterized, and no human safety profile exists.

People taking stimulants, hormone modulators or experimental metabolic compounds without clinician oversight: drug interactions are uncharacterized.

Competitive athletes tested under WADA rules: ERR agonists fall under WADA class S4.5 metabolic modulators as a class, even though SLU-PP-332 is not named separately.

Resting heart rate and blood pressure should be tracked periodically due to community reports of heart-rate changes. (reported by Peptide Dosing Protocols)